CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性多发性骨髓瘤临床实践中 CAR-T 细胞治疗管理与疗效评估的共识指南与推荐：国际骨髓瘤工作组免疫治疗委员会报告
英文原题：Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
查看英文原题
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法在晚期线治疗的难治性多发性骨髓瘤患者中显示出良好前景，缓解率为 73%–98%。迄今已有三种产品获批：伊德卡布他仑赛（ide-cel）和西达基奥仑赛（cilta-cel）获美国食品药品监督管理局、欧洲药品管理局和加拿大卫生部批准（加拿大仅批准 ide-cel），巴西 ANVISA 仅批准 cilta-cel；依卡卡布他仑赛（eque-cel）获中国国家药品监督管理局批准。CAR-T 细胞疗法不同于既往抗骨髓瘤治疗，具有独特毒性，需采取专门的减毒管理策略。因此，国际骨髓瘤工作组组织专家组，为骨髓瘤 CAR-T 细胞疗法的临床应用提供指导。本共识意见由造血细胞移植、细胞疗法及多发性骨髓瘤治疗领域专家制定。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%.
To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel), which was approved by the Chinese National Medical Products Administration. CAR T-cell therapy is different from previous anti-myeloma therapeutics with unique toxic effects that require distinct mitigation strategies.
Thus, a panel of experts from the International Myeloma Working Group was assembled to provide guidance for clinical use of CAR T-cell therapy in myeloma. This consensus opinion is from experts in the field of haematopoietic cell transplantation, cell therapy, and multiple myeloma therapeutics.
论文信息
- 作者
- Lin Y、Qiu L、Usmani S、Joo CW、Costa L、Derman B、Du J、Einsele H
- 单位
- Department of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address: lin.yi@mayo.edu.United States
- 文献类型
- 共识声明 · 综述
- 期刊
- The Lancet. Oncology2024 Aug
- 原文标识
- PubMed 38821074 · DOI 10.1016/S1470-2045(24)00094-9